Sutro Biopharma\u00a0reeled in\u00a0an $85.4 million series E that will advance some early-stage programs as well as its cancer pipeline, which includes a pair of antibody-drug conjugates (ADCs).Of its ADC assets, STRO-001 is in phase 1 for lymphoma and multiple myeloma, and STR-002 is slated to enter the clinic for ovarian and endometrial cancer by early 2019..The financing comes five years after the Bay Area biotech’s\u00a0$26 million\u00a0series D round and brings its total raised to more than $175 million. A few ADCs are already on the market\u2014including Roche’s HER2-targeting breast cancer drug Kadcyla and Spectrum Pharma’s non-Hodgkin lymphoma drug Zevalin\u2014and a number of them are in development.In April, Swiss biotech ADC Therapeutics\u00a0ditched\u00a0a candidate for HER2-positive breast cancers due to toxicity issues in a phase 1 trial. AbbVie\u00a0ended\u00a0an early-stage trial for its ADC designed for solid tumors.<\/p>\n
HiFiBiO Therapeutics has signed a deal with Takeda, to work on antibody therapies for various gastrointestinal diseases, cancers and other disorders.HiFiBiO, which works on antibodies through single-B-cell screening and analysis, will receive upfront, R&D, milestone\u00a0and royalty payments based on antibodies delivered to Takeda for development and sales, but both are keeping\u00a0tight-lipped\u00a0on just how much that\u2019s all worth.\u00a0\u00a0In May, the Cambridge, Massachusetts-based company got off a $37.5 million series B round, coming off a 2017 management shuffle, which saw the biotech hire a new president and CEO in Liang Schweizer, Ph.D., who previously held management roles in cancer research at Sanofi and Bristol-Myers Squibb.<\/p>\n","protected":false},"excerpt":{"rendered":"
Sutro Biopharma nets $85.4M to drive antibody-drug conjugates Sutro Biopharma\u00a0reeled in\u00a0an $85.4 million series E that will advance some early-stage programs as well as its cancer pipeline, which includes a pair of antibody-drug conjugates (ADCs).Of its ADC assets, STRO-001 is in phase 1 for lymphoma and multiple myeloma, and STR-002 is slated to enter the […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[78,2831,1756,554,17637],"industry":[17225],"therapeutic_areas":[17638,17228],"class_list":["post-2833","post","type-post","status-publish","format-standard","hentry","category-notizia","tag-antibody-drug-conjugates","tag-non-hodgkin-lymphoma","tag-sutro-biopharma","tag-takeda","tag-zevalin","industry-pharmaceutical","therapeutic_areas-non-malignant-disorders","therapeutic_areas-oncology"],"acf":[],"yoast_head":"\n